Jaguar Health Approves Sixfold Increase to 2014 Plan Share Reserve

Jaguar Health approved a sixfold increase to its 2014 Stock Incentive Plan share reserve, effective after a November 6 meeting. If Proposal 3 is approved, the reserve will be 2,273,154 shares; if not, it will be 4,260 shares. Maximum shares issuable through incentive stock options will be 163,998 in either case, according to the company.

Original reporting
Published Oct 28, 2026, 9:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 9:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Jaguar Health Approves Sixfold Increase to 2014 Plan Share Reserve — source image
Decision brief

The 30-second read

$JAGXBearishLow
01

Why it matters

The filing expands the pool of shares available for future option grants, which may dilute existing shareholders but could also support talent retention.

02

Market read

A corporate action that modestly increases dilution risk for shareholders of JAGX.

03

What to watch

Potential for the company to limit actual issuances below the maximum, reducing dilution risk.

Relevance 5/10Novelty 5/10Timing: effective immediately after the Nov 6 special meeting

Background

Jaguar Health is a micro‑cap biotech that filed an 8‑K to adjust its stock incentive plan following a Series R preferred dividend.

Company-level read

Ticker impact

$JAGXBearishHigh confidence
Context

Jaguar Health filed an 8‑K announcing a sixfold increase to its 2014 Stock Incentive Plan share reserve, changing the potential pool of issuable shares.

Expected impact

likely modest downward pressure as the market prices in potential dilution

Evidence & confidence

The filing is the first public disclosure of the reserve change and directly expands the pool of shares that could be issued through options.

Market effects

Minimal impact on the broader biotech sector; the change is company‑specific.

Limited to U.S. investors holding JAGX.

Low

Counterpoint

If the increased reserve is used for strategic hires or acquisitions, the dilution could be offset by future growth.

Key entities

  • Jaguar Health, Inc.

    Issuer of the stock incentive plan adjustment.

Related articles

$JAGXMed

Jaguar Health Reports Third Quarter 2026 Financials

Jaguar Health, Inc. (JAGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Jaguar Health Reports Third Quarter 2026 Financials Jaguar’s rare disease intestinal failure development program for microvillus inclusion disease (MVID) and short bowel syndrome for crofelemer powder for oral solution is expected to continue to provide clinical mile

$JAGXMedAI 8/10

Jaguar Health, Inc.: Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure in Third Rare Congenital Enteropathy Disorder

Jaguar Health (JAGX) announced that its drug crofelemer has shown benefits in treating intestinal failure in pediatric patients with GUCY2C gene mutation, reducing parenteral support needs. The company plans to file for FDA approval for MVID in mid-2027. Crofelemer has also shown promise in reducing parenteral support needs in patients with MVID and SBS-IF.

$JAGXMedAI 8/10

Jaguar Health unit treats infant with rare intestinal disorder

Jaguar Health Inc. (JAGX) announced its subsidiary Napo Pharmaceuticals is treating an infant with congenital sodium diarrhea using crofelemer, reducing parenteral support needs by 15%. The company plans to file a New Drug Application for microvillus inclusion disease in mid-2027, with trial data showing significant reductions in parenteral support for pediatric patients.